Disease-Specific Contribution of Pulvinar Dysfunction to Impaired Emotion Recognition in Schizophrenia.
Antígona Martínez, Russell H Tobe, Pablo A Gaspar...
https://pubmed.ncbi.nlm.nih.gov/35237135/Actively Recruiting
Led by Nathan Kline Institute for Psychiatric Research · Updated on 2026-03-13
120
Participants Needed
1
Research Sites
13 weeks
Total Duration
Researchers are studying whether transcranial direct current stimulation tDCS, a non-invasive brain stimulation technique, can improve face emotion recognition in people with schizophrenia. The study focuses on applying tDCS over the brains motion processing area area MT to address difficulties in detecting facial motion, which contribute to social cognition challenges in schizophrenia. Brain activity will be measured using fMRI and EEG while participants view moving and dynamic face stimuli, comparing effects of active versus sham stimulation. Participants include 120 individuals with schizophrenia and 30 healthy controls. Those with schizophrenia will be randomly assigned to receive either active personalized, MR-guided cathodal HD-tDCS targeting area MT or sham stimulation that mimics the sensation without current flow. Each schizophrenia participant will undergo two sessions involving event-related potentials ERP and fMRI with up to 40 minutes of stimulation per session, spaced at least one week apart. Healthy controls will be assessed only at baseline. Participants will complete baseline assessments before randomization and then receive their assigned tDCS intervention during ERP and fMRI visits. Researchers will measure brain region activation related to motion and face emotion recognition, behavioral scores on motion discrimination, face emotion accuracy, and understanding mental states. The study includes comprehensive monitoring of brain responses and behavioral outcomes to evaluate the impact of tDCS over the study period ending in 2030.
CONDITIONS
Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways
O
Odeta Beggel, MA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Nathan Kline Institute for Psychiatric Research
Lead Sponsor
National Institute of Mental Health (NIMH)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Active tDCS (MT+ stimulation) | Sham tDCS (simulated scalp sensation) |
|---|---|---|
| What it is | Transcranial direct current stimulation (tDCS) device intervention over the MT+ cortical region; delivers sustained electrical current. | Sham tDCS simulates the scalp sensation of active stimulation but does not deliver sustained current; serves as a placebo device comparator. |
| Role in the trial | Investigational intervention arm; tests effects of real tDCS on cognitive and visual pathway activation. | Comparator control arm; evaluates expectation and placebo effects without real current. |
| Primary use | Investigated to determine if MT+ tDCS can improve visual pathway activation, cognition, and emotion recognition in schizophrenia or schizoaffective disorder. | Acts as a placebo comparator to control for expectancy; does not actively modulate visual pathways or cognition. |
| How it is given or performed | tDCS electrodes placed over MT+ region; sustained current delivered during study days with simultaneous fMRI/ERP measurement and cognitive testing. | Electrodes placed identically; ramp-up/ramp-down stimulation is delivered briefly to mimic sensations, but no sustained current is applied. |
| Evidence status | Efficacy in modulating cognitive or visual pathway deficits is not yet established; results pending for this trial. Prior literature supports rationale for targeting visual/emotional pathways in schizophrenia. | No active intervention; not expected to affect visual pathway activation or cognitive performance. |
| Important limitations | Device efficacy and clinical impact in schizophrenia remain to be proven. Limitations include device tolerability, adherence, and unknown effect magnitude; study population is restricted to moderately ill adults. | Does not represent clinical treatment; limitations relate to placebo response and expectation effect but do not address clinical improvement. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 to 2 visits for assessments
Duration - Up to 2 weeks
Participants complete baseline clinical and physiological assessments including brain imaging and behavioral testing.
2 visits before intervention
Duration - Approximately 3 to 4 weeks
Participants with schizophrenia receive two sessions of either active or sham tDCS during ERP and fMRI assessments spaced at least one week apart.
2 stimulation visits
Duration - Until study completion in 2030
Researchers analyze brain activation, behavioral outcomes, and physiological data collected during the trial.
No participant visits; remote data processing
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Antígona Martínez, Russell H Tobe, Pablo A Gaspar...
https://pubmed.ncbi.nlm.nih.gov/35237135/Nathan Kline Institute for Psychiatric Research
Lead Sponsor
National Institute of Mental Health (NIMH)
Collaborating Sponsor